Amiodarone pulmonary toxicity.
The amount of literature on amiodarone pulmonary toxicity (APT) peaked in 1983-1984 with several hundred cases reported cumulatively, and declined thereafter. Since the mid-1990s, publications have increased, which suggests that APT remains a current problem in clinical practice. Amiodarone remains difficult to diagnose noninvasively, and although the outcome is good in the majority of patients, not all cases of APT can be controlled satisfactorily.
Camus
Philippe
P
Department of Pulmonary Medicine and Critical Care, Centre Hospitalier et Université de Bourgogne, F-2100 Dijon, France. phillipe.camus@chu-dijon.fr
Martin
William J
WJ
Rosenow
Edward C
EC
D000638:Amiodarone / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D018893:Bronchoalveolar Lavage; D006801:Humans; D007049:Iatrogenic Disease; D008168:Lung / Q000187:drug effects; D010994:Pleura / Q000187:drug effects / Q000473:pathology; D011014:Pneumonia / Q000139:chemically induced; D012129:Respiratory Function Tests
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone